Navigation Links
Radient Pharmaceuticals Asks DHS Holding Co. to Retract News Release Saying It Will Enter Into Talks With Radient Pharmaceuticals Corporation
Date:11/15/2011

TUSTIN, Calif., Nov. 15, 2011 /PRNewswire/ -- On November 14, 2011, DHS Holding Co. (DHS) issued a press release announcing it will enter into preliminary talks with Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), to discuss business opportunities that would benefit both parties.  However, that press release was issued without our approval and we do not intend to have any further discussions, or enter into any business opportunities with DHS.

On today's date, our attorneys requested DHS to immediately retract the press release at issue.

The following table is intended to provide the latest information on Radient's business metrics.Radient's Business MetricsCash on hand: $54,000*

*Approximate amount as of November 15, 2011Common Shares Outstanding:  746 million*

*Approximate number as of November 15, 2011.

  5 billion shares authorized.Outstanding Warrants & Options:  110 million*

*Approximate number as of  November 15, 2011About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Radient Contact:Paul Knopick
E & E Communications
pknopick@eandecommunications.com
(Tel:) 949.707.5365


'/>"/>

SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
2. Merriman Capital Announces Sponsorship of Radient Pharmaceuticals Corporation on OTCQX
3. Radient Pharmaceuticals Corporation Joins OTCQX
4. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
5. The Outlook for Pharmaceuticals in South East Asia
6. The Outlook for Pharmaceuticals in Western Europe
7. The Outlook for Pharmaceuticals in Central & Eastern Europe
8. The Outlook for Pharmaceuticals in the Middle East and North Africa
9. The Outlook for Pharmaceuticals in Brazil, Russia, India & China
10. The Outlook for Pharmaceuticals in Latin America
11. Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):